Abbott cuts sales growth forecast on baby formula recall

Jefferey Metcalfe

Packages of BinaxNOW COVID-19 Antigen Self Test, manufactured by Abbott Laboratories, are seen in a store in Manhattan, New York, U.S., November 12, 2021. REUTERS/Andrew Kelly/File Photo

Register now for FREE unlimited access to

April 20 (Reuters) – Abbott Laboratories (ABT.N) on Wednesday lowered its full-year sales growth forecast, citing the voluntary recall of some infant formula products, including Similac, even as COVID-19 testing demand helped the company beat quarterly estimates.

Abbott recalled certain powdered formulas made at its Michigan facility during the quarter after they were linked to infant illnesses. As a result, sales at its nutrition unit declined 7% in the quarter. read more

“We now forecast total company organic sales growth to be in the mid- to high single digits, which is somewhat lower than our prior forecast of high single digits due to the recent recall,” Chief Financial Officer Robert Funck said in an earnings call.

Register now for FREE unlimited access to

The company said the testing of samples by Abbott and the FDA related to the recall have all come back negative for the presence of the bacteria that caused the reported illnesses. The FDA did not immediately respond to Reuters request for comment.

Abbott called the recall a “short-term hindrance” and said it was working closely with the regulator and has begun implementing corrective actions and enhancements to the facility.

Abbott shares rose 2.4% to $122.90 in morning trade as some analysts said the comments during the conference call allayed worries over the recall.

Despite the recall and supply chain issues, Abbott beat quarterly profit and revenue estimates in the first quarter.

The company reported $3.3 billion in COVID-19 test sales in the quarter, adding that it now expects to record nearly $4.5 billion in 2022, most of which it expects to log in the first half. Its previous estimate was $2.5 billion.

Abbott said it still expects 2022 adjusted profit per share to be at least $4.70. Analysts on average expected profit of $4.83.

Atlantic Equities analyst James Mainwaring called the guidance reiteration “prudent” in light of the recall and ongoing supply chain challenges.

Register now for FREE unlimited access to

Reporting by Mrinalika Roy and Bhanvi Satija in Bengaluru; Editing by Amy Caren Daniel and Ankur Banerjee

Our Standards: The Thomson Reuters Trust Principles.

Next Post

Elemy Launches Ecademy in Texas to Address Growing Need for Childhood Mental Health Experts | Business

AUSTIN, Texas–(BUSINESS WIRE)–Apr 14, 2022– Elemy ( ), the nationwide provider of childhood behavioral and mental healthcare, today announced plans to increase healthcare workers in the state of Texas to keep up with the growing demand of families seeking help for children with autism and other healthcare issues. The […]